Modjtahedi, Helmout - Kingston University

个人简介

2012 - present Professor of Cancer Biology 2010 - 2012 Reader in Cancer Therapeutics 1989 - 1993 PhD, Tumour Immunology, Institute of Cancer Research, University of London 1986 - 1989 First Class BSc Honours in Medical Laboratory Science, University of Ulster

研究领域

Biological and clinical significance of growth factor receptors with tyrosine kinase activity and cancer stem cells in human malignancies Targeted therapy of human cancers using monoclonal antibodies and small molecule tyrosine kinase inhibitors Tumour biomarkers and drug-resistance in cancer Identification of novel therapeutic targets and diagnostic markers using monoclonal antibody technology.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Ioannou, Nikolaos, Seddon, Alan, Dalgleish, Angus, Mackintosh, David, Solca, Flavio and Modjtahedi, Helmout (2016) Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition. International Journal Of Oncology, 48(3), pp. 908-918. ISSN (print) 1019-6439 Puvanenthiran, Soozana, Essapen, Sharadah, Seddon, Alan and Modjtahedi, Helmout (2016) Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of the HER inhibitors and cytotoxic drugs. International Journal Of Oncology, ISSN (print) 1019-6439 (Epub Ahead of Print) Bazzi, Samer, Modjtahedi, Helmout, Mudan, Satvinder, Akle, Charles and Bahr, Georges M (2015) Analysis of the immunomodulatory properties of two heat-killed mycobacterial preparations in a human whole blood model. Immunobiology, 220(12), pp. 1293-1304. ISSN (print) 0171-2985 Khelwatty, Said A., Essapen, Sharadah, Seddon, Alan M., Fan, Zhen and Modjtahedi, Helmout (2015) Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. British Journal of Cancer, 113(7), pp. 1010-1019. ISSN (print) 0007-0920 Khelwatty, Said Abdullah, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan and Modjtahedi, Helmout (2014) Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival. PloS one, 9(3), e91139. ISSN (print) 1932-6203 Modjtahedi, Helmout, Cho, Byoung Chul, Michel, Martin C and Solca, Flavio (2014) A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn-Schmiedeberg's archives of pharmacology, ISSN (print) 0028-1298 Modjtahedi, Helmout and Eccles, Suzanne (2014) GA201: a novel humanized and glycoengineered anti-EGFR antibody. Clinical Cancer Research, 20(4), pp. 1053-1054. ISSN (print) 1078-0432 Polycarpou, Elena, Meira, Lisiane B, Carrington, Simon, Tyrrell, Elizabeth, Modjtahedi, Helmout and Carew, Mark A (2013) Resveratrol 3-O-d-glucuronide and resveratrol 4'-O-d-glucuronide inhibit colon cancer cell growth: Evidence for a role of A3 adenosine receptors, cyclin D1 depletion, and G1 cell cycle arrest. Molecular Nutrition and Food Research, 57(10), pp. 1708-1717. ISSN (print) 1613-4125 Ioannou, Nikolaos, Seddon, Alan M., Dalgleish, Angus, Mackintosh, David and Modjtahedi, Helmout (2013) Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC Cancer, 13(41), ISSN (print) 1471-2407 Modjtahedi, Helmout, Ioannou, Nikolaos, Dalgleish, Angus, Mackintosh, David and Seddon, Alan M. (2013) Co-targeting of HER family members and IGF-IR in pancreatic cancer. International Journal Of Molecular Medicine, 32, S40-S40. ISSN (print) 1107-3756 Khelwatty, Said Abdullah, Essapen, Sharadah, Seddon, Alan Michael and Modjtahedi, Helmout (2013) Prognostic significance and targeting of HER family in colorectal cancer. Frontiers in Bioscience, 18(2), pp. 394-421. ISSN (print) 1093-9946 Modjtahedi, Helmout, Ali, Sumaira and Essapen, Sharadah (2012) Therapeutic application of monoclonal antibodies in cancer: advances and challenges. British Medical Bulletin, 104(1), pp. 41-59. ISSN (print) 0007-1420 Modjtahedi, H., Khelwatty, S.A., Kirk, R.S., Seddon, A.M., Essapen, S., Del Vecchio, C.A., Wong, A.J. and Eccles, S. (2012) Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. British Journal of Cancer, 106, pp. 883-888. ISSN (print) 0007-0920 Ioannou, N., Seddon, A.M., Dalgleish, A., Mackintosh, D. and Modjtahedi, H. (2012) Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer. Frontiers in Bioscience, 17(1), pp. 2698-2724. ISSN (print) 1093-9946 Ioannou, N, Dalgleish, A G, Seddon, A M, Mackintosh, D, Guertler, U, Solca, F and Modjtahedi, H (2011) Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. British Journal of Cancer, 105(10), pp. 1554-1562. ISSN (print) 0007-0920 Khelwatty, Said Abdullah, Essapen, Sharadah, Seddon, Alan M. and Modjtahedi, Helmout (2011) Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. International Journal of Oncology, 39(2), pp. 483-491. ISSN (print) 1019-6439 Shafi, Shahida, Lamb, David, Modjtahedi, Helmout and Ferns, Gordon (2010) Periadventitial delivery of anti-EGF receptor antibody inhibits neointimal macrophage accumulation after angioplasty in a hypercholesterolaemic rabbit. International Journal Of Experimental Pathology, 91(3), pp. 224-234. ISSN (print) 0959-9673 Modjtahedi, Helmout and Essapen, Sharadah (2009) Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anti-Cancer Drugs, 20(10), pp. 851-855. ISSN (print) 0959-4973 Cunningham, Matthew P., Thomas, Hilary, Marks, Christopher, Green, Margaret, Fan, Zhen and Modjtahedi, Helmout (2008) Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. International Journal of Oncology, 33(5), pp. 1107-1113. ISSN (print) 1019-6439 Cunningham, Matthew P., Thomas, Hilary, Fan, Zhen and Modjtahedi, Helmout (2006) Responses of human colorectal tumor cells to treatment with the anti–epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. Cancer Research, 66(15), pp. 7708-7715. ISSN (print) 0008-5472 Cunningham, Matthew P., Essapen, Sharadah, Thomas, Hilary, Green, Margaret, Lovell, David P., Topham, Clare, Marks, Christopher and Modjtahedi, Helmout (2005) Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. International Journal of Oncology, 27(2), pp. 317-325. ISSN (print) 1019-6439 Essapen, Sharadah, Thomas, Hilary, Green, Margaret, De Vries, Corrine, Cook, Martin G., Marks, Christopher, Topham, Clare and Modjtahedi, Helmout (2004) The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathalogical parameters. International Journal of Oncology, 24(2), pp. 241-248. ISSN (print) 1019-6439 Modjtahedi, Helmout, Moscatello, David K., Box, Gary, Green, Margaret, Shotton, Christine, Lamb, David J., Reynolds, Lesley J., Wong, Albert J., Dean, Christopher, Thomas, Hilary and Eccles, Suzanne (2003) Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti EGFR MAb ICR62: A two-pronged attack for tumour therapy. International Journal of Cancer, 105(2), pp. 273-280. ISSN (print) 0020-7136